The practical rationale for combination protocols is straightforward: BPC-157 targets local tissue repair (particularly GI, musculoskeletal, and neural) through signaling pathways that promote growth factor expression and cell survival at injury sites, while TB-500 operates more systemically particularly through vascular remodeling, cardiac progenitor activation, and direct anti-inflammatory cytokine modulation
It clears the bloodstream in under thirty minutes, yet users claim effects lasting days
Manufactured under controlled laboratory conditions, our AOD-9604 peptide is produced to support consistency, purity, and stability for research handling and analytical investigation
[1] In a 12 week randomised clinical trial, subjects receiving AOD9604 lost, on average, 1.8 kg more than those receiving placebo